Hot Features
Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
NeuroSense Provides Business Update and Third Quarter 2024 Financial Results PR Newswire CAMBRIDGE, Mass., Dec. 18, 2024 CAMBRIDGE, Mass., Dec. 18, 2024 /PRNewswire/ -- NeuroSense Therapeutics...
NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC PR Newswire CAMBRIDGE, Mass., Dec. 11, 2024 The Type C meeting with the FDA, combined with the recent 18-month Phase...
NeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALS PR Newswire CAMBRIDGE, Mass., Dec. 4, 2024 In participants who...
NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price PR Newswire CAMBRIDGE, Mass., Dec. 2, 2024 CAMBRIDGE, Mass., Dec. 2, 2024 /PRNewswire/ -- NeuroSense...
NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND PR Newswire CAMBRIDGE, Mass., Nov. 21, 2024 CAMBRIDGE, Mass., Nov. 21, 2024 /PRNewswire/ -- NeuroSense...
NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission PR Newswire CAMBRIDGE, Mass., Oct. 28, 2024 Meeting discussion to focus on finalizing Phase 3 study design...
New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients PR Newswire CAMBRIDGE, Mass., Oct. 24, 2024 Groundbreaking PARADIGM Trial Offers New Hope for ALS Treatment CAMBRIDGE...
NeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates PR Newswire CAMBRIDGE, Mass., Oct. 15, 2024 Dossier submission planned...
NeuroSense Therapeutics Plans to File for Early Commercialization of ALS Treatment in Canada PR Newswire CAMBRIDGE, Mass., Oct. 9, 2024 The preparations for the regulatory submission for early...
NeuroSense Therapeutics Announces Acceptance of Two PrimeC Abstracts at the 2024 NEALS Annual Meeting PR Newswire CAMBRIDGE, Mass., Oct. 7, 2024 CAMBRIDGE, Mass., Oct. 7, 2024 /PRNewswire/...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.4499 | 48.376344086 | 0.93 | 1.42 | 0.81 | 705367 | 1.10574247 | CS |
| 4 | 0.4599 | 49.9891304348 | 0.92 | 1.42 | 0.8 | 397189 | 1.05176285 | CS |
| 12 | 0.0799 | 6.14615384615 | 1.3 | 1.42 | 0.8 | 236019 | 1.11961891 | CS |
| 26 | 0.4499 | 48.376344086 | 0.93 | 1.5 | 0.512 | 314281 | 0.99797744 | CS |
| 52 | 0.5824 | 73.0282131661 | 0.7975 | 2.33 | 0.512 | 263346 | 1.17855987 | CS |
| 156 | -1.6901 | -55.0521172638 | 3.07 | 8.18 | 0.4 | 977432 | 3.40024445 | CS |
| 260 | -3.1701 | -69.6725274725 | 4.55 | 8.18 | 0.4 | 975265 | 3.40124688 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
